349 related articles for article (PubMed ID: 16557546)
1. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro.
Paeshuyse J; Kaul A; De Clercq E; Rosenwirth B; Dumont JM; Scalfaro P; Bartenschlager R; Neyts J
Hepatology; 2006 Apr; 43(4):761-70. PubMed ID: 16557546
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes.
Watashi K; Hijikata M; Hosaka M; Yamaji M; Shimotohno K
Hepatology; 2003 Nov; 38(5):1282-8. PubMed ID: 14578868
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo.
Inoue K; Umehara T; Ruegg UT; Yasui F; Watanabe T; Yasuda H; Dumont JM; Scalfaro P; Yoshiba M; Kohara M
Hepatology; 2007 Apr; 45(4):921-8. PubMed ID: 17393519
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of antiviral activity against hepatitis C virus in vitro by interferon combination therapy.
Okuse C; Rinaudo JA; Farrar K; Wells F; Korba BE
Antiviral Res; 2005 Jan; 65(1):23-34. PubMed ID: 15652968
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811.
Goto K; Watashi K; Murata T; Hishiki T; Hijikata M; Shimotohno K
Biochem Biophys Res Commun; 2006 May; 343(3):879-84. PubMed ID: 16564500
[TBL] [Abstract][Full Text] [Related]
6. Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection.
Watashi K
Curr Opin Investig Drugs; 2010 Feb; 11(2):213-24. PubMed ID: 20112171
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of intracellular hepatitis C virus replication by nelfinavir and synergistic effect with interferon-alpha.
Toma S; Yamashiro T; Arakaki S; Shiroma J; Maeshiro T; Hibiya K; Sakamoto N; Kinjo F; Tateyama M; Fujita J
J Viral Hepat; 2009 Jul; 16(7):506-12. PubMed ID: 19302339
[TBL] [Abstract][Full Text] [Related]
8. Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells.
Lin K; Kwong AD; Lin C
Antimicrob Agents Chemother; 2004 Dec; 48(12):4784-92. PubMed ID: 15561857
[TBL] [Abstract][Full Text] [Related]
9. New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1.
Taylor DR; Puig M; Darnell ME; Mihalik K; Feinstone SM
J Virol; 2005 May; 79(10):6291-8. PubMed ID: 15858013
[TBL] [Abstract][Full Text] [Related]
10. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.
Abe H; Imamura M; Hiraga N; Tsuge M; Mitsui F; Kawaoka T; Takahashi S; Ochi H; Maekawa T; Hayes CN; Tateno C; Yoshizato K; Murakami S; Yamashita N; Matsuhira T; Asai K; Chayama K
J Hepatol; 2011 Jul; 55(1):11-8. PubMed ID: 21145867
[TBL] [Abstract][Full Text] [Related]
11. Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
Coelmont L; Kaptein S; Paeshuyse J; Vliegen I; Dumont JM; Vuagniaux G; Neyts J
Antimicrob Agents Chemother; 2009 Mar; 53(3):967-76. PubMed ID: 19104013
[TBL] [Abstract][Full Text] [Related]
12. Hairpin ribozymes in combination with siRNAs against highly conserved hepatitis C virus sequence inhibit RNA replication and protein translation from hepatitis C virus subgenomic replicons.
Jarczak D; Korf M; Beger C; Manns MP; Krüger M
FEBS J; 2005 Nov; 272(22):5910-22. PubMed ID: 16279954
[TBL] [Abstract][Full Text] [Related]
13. Application of the trak-C HCV core assay for monitoring antiviral activity in HCV replication systems.
Cagnon L; Wagaman P; Bartenschlager R; Pietschmann T; Gao T; Kneteman NM; Tyrrell DL; Bahl C; Niven P; Lee S; Simmen KA
J Virol Methods; 2004 Jun; 118(1):23-31. PubMed ID: 15158065
[TBL] [Abstract][Full Text] [Related]
14. In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease.
Liu R; Abid K; Pichardo J; Pazienza V; Ingravallo P; Kong R; Agrawal S; Bogen S; Saksena A; Cheng KC; Prongay A; Njoroge FG; Baroudy BM; Negro F
J Antimicrob Chemother; 2007 Jan; 59(1):51-8. PubMed ID: 17151003
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for the non-immunosuppressive character of the cyclosporin A analogue Debio 025.
Landrieu I; Hanoulle X; Bonachera F; Hamel A; Sibille N; Yin Y; Wieruszeski JM; Horvath D; Wei Q; Vuagniaux G; Lippens G
Biochemistry; 2010 Jun; 49(22):4679-86. PubMed ID: 20423153
[TBL] [Abstract][Full Text] [Related]
16. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy.
Watashi K; Shimotohno K
Rev Med Virol; 2007; 17(4):245-52. PubMed ID: 17299803
[TBL] [Abstract][Full Text] [Related]
17. Establishment of hepatitis C virus replicon cell lines possessing interferon-resistant phenotype.
Namba K; Naka K; Dansako H; Nozaki A; Ikeda M; Shiratori Y; Shimotohno K; Kato N
Biochem Biophys Res Commun; 2004 Oct; 323(1):299-309. PubMed ID: 15351737
[TBL] [Abstract][Full Text] [Related]
18. Antiviral action of interferon-alpha against hepatitis C virus replicon and its modulation by interferon-gamma and interleukin-8.
Jia Y; Wei L; Jiang D; Wang J; Cong X; Fei R
J Gastroenterol Hepatol; 2007 Aug; 22(8):1278-85. PubMed ID: 17565587
[TBL] [Abstract][Full Text] [Related]
19. Effects of immunosuppressants on the progression of hepatitis C in hepatitis C virus-positive renal transplantation and the usefulness of interferon therapy.
Nanmoku K; Imaizumi R; Tojimbara T; Nakajima I; Fuchinoue S; Sakamoto N; Watanabe M; Teraoka S
Transplant Proc; 2008 Sep; 40(7):2382-5. PubMed ID: 18790241
[TBL] [Abstract][Full Text] [Related]
20. Anti-HCV activities of selective polyunsaturated fatty acids.
Leu GZ; Lin TY; Hsu JT
Biochem Biophys Res Commun; 2004 May; 318(1):275-80. PubMed ID: 15110784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
